Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel
暂无分享,去创建一个
Birgit Funke | Eden Haverfield | Ana Morales | Hugh Watkins | Daniela Macaya | Roddy Walsh | Nicola Whiffin | James S Ware | John Garcia | Christopher Semsarian | Kate Thomson | Steven M Harrison | Stuart Cook | Melissa A Kelly | Colleen Caleshu | Jillian Buchan | Zena Wolf | Mitchell W Dillon | Jan D H Jongbloed | Arjun Manrai | Kate Orland | Gabriele Richard | Katherine Spoonamore | Matthew Thomas | Lisa M Vincent | Jodie Ingles | J Peter van Tintelen | Ray Hershberger | C. Caleshu | S. Cook | J. Buchan | J. Ware | H. Watkins | D. Macaya | B. Funke | N. Whiffin | S. Harrison | John Garcia | R. Hershberger | C. Semsarian | J. Ingles | A. Manrai | G. Richard | J. P. van Tintelen | J. Jongbloed | R. Walsh | K. Thomson | M. Kelly | E. Haverfield | A. Morales | L. Vincent | Kate M Orland | Katherine G Spoonamore | Z. Wolf | Matthew Thomas | Kate M. Orland | J. V. van Tintelen | Eden V. Haverfield | K. Thomson | Zena T. Wolf | J. P. van Tintelen | M. Kelly
[1] Jonathan S. Berg,et al. Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels , 2019, Genome Medicine.
[2] G. Jarvik,et al. Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants. , 2016, American journal of human genetics.
[3] Hencher Han-Chih Lee,et al. Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies. , 2019, The Clinical biochemist. Reviews.
[4] Euan Ashley,et al. Insights into Human β-Cardiac Myosin Function from Single Molecule and Single Cell Studies , 2009, Journal of cardiovascular translational research.
[5] R. Nussbaum,et al. Modeling the ACMG/AMP Variant Classification Guidelines as a Bayesian Classification Framework , 2018, Genetics in Medicine.
[6] Heidi L Rehm,et al. ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.
[7] Matthew S. Lebo,et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.
[8] D. MacArthur,et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.
[9] Michael J Ackerman,et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. , 2010, Journal of the American College of Cardiology.
[10] Jyothsna Giri,et al. Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare , 2019, Pharmacogenomics and personalized medicine.
[11] Andrew J. Hill,et al. Analysis of protein-coding genetic variation in 60,706 humans , 2015, bioRxiv.
[12] C. Bustamante,et al. Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation , 2016, Proceedings of the National Academy of Sciences.
[13] Michael J Ackerman,et al. Implantable cardioverter-defibrillator explantation for overdiagnosed or overtreated congenital long QT syndrome. , 2016, Heart rhythm.
[14] Barry J Maron,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.
[15] D. MacArthur,et al. Using high-resolution variant frequencies to empower clinical genome interpretation , 2016, Genetics in Medicine.
[16] L. Køber,et al. One third of Danish hypertrophic cardiomyopathy patients have mutations in MYH7 rod region , 2005, European Journal of Human Genetics.
[17] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[18] Lea M. Starita,et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework , 2019, Genome Medicine.
[19] D. G. MacArthur,et al. Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.
[20] Vijai Joseph,et al. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Byers,et al. The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories , 2015, Genetics in Medicine.
[22] D. Hedges,et al. Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.
[23] Sivakumar Gowrisankar,et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing , 2014, Genetics in Medicine.
[24] S. Letovsky,et al. Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification , 2015, Genetics in Medicine.
[25] Matthew S. Lebo,et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.
[26] J. Towbin,et al. Left ventricular non-compaction cardiomyopathy , 2015, The Lancet.
[27] W. McKenna,et al. Left ventricular noncompaction and cardiomyopathy: cause, contributor, or epiphenomenon? , 2008, Current opinion in cardiology.
[28] Trevor J Pugh,et al. A systematic approach to assessing the clinical significance of genetic variants , 2013, Clinical genetics.
[29] Jonathan R. Weir-McCall,et al. Left Ventricular Noncompaction Anatomical Phenotype or Distinct Cardiomyopathy ? , 2016 .